col blocks we are bridge builder col blocks
COVID answers in Scientific Journals all over the world


74 Results       Page 1

 [1] 
Oxford University Press: Journal of Antimicrobial Chemotherapy
  original article Date Title Authors   All Authors
1 [GO] 2026―Jan―28 Correction to: Comment on: Antiviral effect of Evusheld in COVID-19 hospitalized patients infected with pre-Omicron or Omicron variants: a modelling analysis of the randomized DisCoVeRy trial
2 [GO] 2025―Oct―15 Time to anti-cancer treatment resumption after SARS-CoV-2 infection in patients with active haematological diseases undergoing combined antiviral treatments E Matteini, C Pinnetti, F Frondizi, E Rando, M Chiuchiarelli, E Metafuni, et al. (+10)
3 [GO] 2025―Sep―01 Placental transfer of medications to treat COVID-19, molnupiravir, favipiravir and nirmatrelvir/ritonavir, in the ex vivo human cotyledon model Solene Labaye, Fatima Djellali, Gilles Peytavin, Laurent Mandelbrot
4 [GO] 2025―Jun―27 Correction to: Pandemic human-associated extended-spectrum β-lactamase-producing Escherichia coli lineages of ST38, ST131 and ST141 identified in Viennese dogs
5 [GO] 2025―May―14 Decline of antimicrobial resistance in Pseudomonas aeruginosa bacteraemia following the COVID-19 pandemic: a longitudinal observational study Yulia Butscheid, Pascal M Frey, Marc Pfister, Lisa Pagani, Roger D Kouyos, Thomas C Scheier, et al. (+3)
6 [GO] 2025―Mar―19 Pandemic human-associated extended-spectrum β-lactamase-producing Escherichia coli lineages of ST38, ST131 and ST141 identified in Viennese dogs Pia Saria, Pavlos G Doulidis, Amélie Desvars-Larrive, Adrienn Gréta Tóth, Iwan A Burgener, Alexandro Rodríguez-Rojas, Olga Makarova
7 [GO] 2025―Jan―13 Efficacy and safety of antiviral therapies for the treatment of persistent COVID-19 in immunocompromised patients since the Omicron surge: a systematic review Caroline Hirsch, Nina Kreuzberger, Nicole Skoetz, Ina Monsef, Stefan Kluge, Christoph D Spinner, Jakob J Malin
8 [GO] 2025―Jan―13 Antiviral effect of Evusheld in COVID-19 hospitalized patients infected with pre-omicron or omicron variants: a modelling analysis of the randomized DisCoVeRy trial-authors’ response Maxime Beaulieu, Jérémie Guedj
9 [GO] 2024―Nov―05 Comment on: Antiviral effect of Evusheld in COVID-19 hospitalized patients infected with pre-Omicron or Omicron variants: a modelling analysis of the randomized DisCoVeRy trial Alexis Lacout, Xavier Azalbert, Corinne Reverbel, Jean-François Lesgards, Dominique Cerdan, Valère Lounnas, et al. (+3)
10 [GO] 2024―Oct―07 Suboptimal response to combination therapy with tixagevimab/cilgavimab and remdesivir for persistent SARS-CoV-2 infections in immunocompromised patients-authors’ response Tzong-Yow Wu, Pao-Yu Chen, Jann-Tay Wang, Wang-Da Liu, Yee-Chun Chen, Shan-Chwen Chang
11 [GO] 2024―Oct―07 Real-world effectiveness of early anti-SARS therapy in severely immunocompromised COVID-19 outpatients during the SARS-CoV-2 omicron variant era: a propensity score-adjusted retrospective cohort study Héctor Pinargote-Celorio, Óscar Moreno-Pérez, Pilar González-De-La-Aleja, Jara Llenas-García, Pedro María Martínez Pérez-Crespo, Juan-Carlos Rodríguez-Díaz, et al. (+4)
12 [GO] 2024―Sep―27 Outcomes of patients hospitalized in ward settings for COVID-19 pneumonia with or without early empirical antibiotics A Kopp-Derouet, S Diamantis, S Chevret, A Tazi, R Burlacu, J P Kevorkian, et al. (+3)
13 [GO] 2024―Sep―09 A retrospective propensity-score-matched cohort study of the impact of procalcitonin testing on antibiotic use in hospitalized patients during the first wave of COVID-19 Jonathan A T Sandoe, Detelina Grozeva, Mahableshwar Albur, Stuart E Bond, Lucy Brookes-Howell, Paul Dark, et al. (+24)
14 [GO] 2024―Sep―05 Antiviral effect of Evusheld in COVID-19 hospitalized patients infected with pre-Omicron or Omicron variants: a modelling analysis of the randomized DisCoVeRy trial Maxime Beaulieu, Alexandre Gaymard, Clément Massonnaud, Nathan Peiffer-Smadja, Maude Bouscambert-Duchamp, Guislaine Carcelain, et al. (+6)
15 [GO] 2024―Jul―29 Comment on: Suboptimal response to combination therapy with tixagevimab/cilgavimab and remdesivir for persistent SARS-CoV-2 infections in immunocompromised patients Federico Barone, Andrea Giacomelli, Giacomo Casalini, Mario Corbellino, Alessia Lai, Andrea Gori, Spinello Antinori
16 [GO] 2024―Jul―10 Influence of the COVID-19 pandemic on the defined daily dose of antimicrobials in patients requiring elective and emergency surgical procedures Fátima Aguilar-Del-Castillo, Miriam Álvarez-Aguilera, José Tinoco-González, Iván Vaca, Laura Herrera-Hidalgo, María Paniagua, et al. (+3)
17 [GO] 2024―Jul―10 Extended remdesivir administration in haematological patients with malignancies and COVID-19 during the Omicron era: safety and outcomes Emmanuelle Gras, Tommaso Francesco Aiello, Mariana Chumbita, Antonio Gallardo-Pizarro, Patricia Monzó-Gallo, Christian Teijón-Lumbreras, et al. (+6)
18 [GO] 2024―Jun―06 The cost-effectiveness of procalcitonin for guiding antibiotic prescribing in individuals hospitalized with COVID-19: part of the PEACH study Edward J D Webb, Daniel Howdon, Rebecca Bestwick, Natalie King, Jonathan A T Sandoe, Joanne Euden, et al. (+129)
19 [GO] 2024―May―31 Effectiveness of nirmatrelvir/ritonavir and molnupiravir in non-hospitalized adults with COVID-19: systematic review and meta-analysis of observational studies Yonatan M Mesfin, Joseph E Blais, Kelemu Tilahun Kibret, Teketo Kassaw Tegegne, Benjamin J Cowling, Peng Wu
20 [GO] 2024―May―09 Comment on: Molnupiravir for the treatment of non-severe COVID-19: a systematic review and meta-analysis of 14 randomized trials with 34 570 patients I Wen Chen, Li-Chen Chang, Kuo-Chuan Hung
21 [GO] 2024―Apr―11 Human bronchopulmonary disposition and plasma pharmacokinetics of oral bemnifosbuvir (AT-527), an experimental guanosine nucleotide prodrug for COVID-19 Xiao-Jian Zhou, Arantxa Horga, Adeep Puri, Lee Winchester, Maureen Montrond, Keith Pietropaolo, et al. (+3)
22 [GO] 2024―Mar―28 Suboptimal response to combination therapy with tixagevimab/cilgavimab and remdesivir for persistent SARS-CoV-2 infections in immunocompromised patients Tzong-Yow Wu, Pao-Yu Chen, Jann-Tay Wang, Wang-Da Liu, Yee-Chun Chen, Shan-Chwen Chang
23 [GO] 2024―Feb―22 The relationship between viral clearance rates and disease progression in early symptomatic COVID-19: a systematic review and meta-regression analysis Shivani Singh, Simon Boyd, William H K Schilling, James A Watson, Mavuto Mukaka, Nicholas J White
24 [GO] 2024―Feb―21 COVID-19 hospitalization risk after outpatient nirmatrelvir/ritonavir use, January to August 2022, North Carolina Heather I Henderson, David A Wohl, William A Fischer, Luther A Bartelt, David van Duin, Deana M Agil, et al. (+5)
25 [GO] 2023―Dec―12 Nirmatrelvir/ritonavir for COVID-19: an overview of systematic reviews Mario Cruciani, Ilaria Pati, Francesca Masiello, Simonetta Pupella, Vincenzo De Angelis
26 [GO] 2023―Nov―23 SARS-CoV-2 genomics and impact on clinical care for COVID-19 Ramon Lorenzo-Redondo, Alexandre Machado de Sant’Anna Carvalho, Judd F Hultquist, Egon A Ozer
27 [GO] 2023―Nov―23 An overview of COVID-19 global epidemiology and discussion of potential drivers of variable global pandemic impacts Polly Ashmore, Emma Sherwood
28 [GO] 2023―Nov―23 Innovative approaches to COVID-19 medical countermeasure development Gavin H Harris, Amesh A Adalja
29 [GO] 2023―Nov―23 COVID-19 therapeutics: stewardship in England and considerations for antimicrobial resistance Sabine Bou-Antoun, Sakib Rokadiya, Diane Ashiru-Oredope, Alicia Demirjian, Emma Sherwood, Nicholas Ellaby, et al. (+15)
30 [GO] 2023―Nov―23 The evaluation of a multi-day testing approach with antigen lateral flow devices for people eligible for community-based COVID-19 treatments Tom Fowler, Alasdair Fellows, Rachael MacISaac, Olumide Kolade, Bhupinder Singh, Adam Eccles, et al. (+2)
31 [GO] 2023―Nov―23 Lessons identified for a future pandemic Neil Cunningham, Susan Hopkins
32 [GO] 2023―Oct―26 Prevalence of antibiotic prescribing in COVID-19 patients in China and other low- and middle-income countries during the pandemic (December 2019-March 2021): a systematic review and meta-analysis Wenjuan Cong, Hung-Yuan Cheng, Beth Stuart, Binjuan Liu, Yunyi Tang, Yi Wang, et al. (+4)
33 [GO] 2023―Oct―26 Molnupiravir for the treatment of non-severe COVID-19: a systematic review and meta-analysis of 14 randomized trials with 34 570 patients-authors’ response Mingyao Sun, Honghao Lai, Zhigang Zhang, Long Ge
34 [GO] 2023―Sep―27 Correction to: Effect of dapagliflozin on COVID-19 infection and risk of hospitalization
35 [GO] 2023―Sep―18 Effects of remdesivir on SARS-CoV-2 viral dynamics and mortality in viraemic patients hospitalized for COVID-19 Karl Hagman, Magnus Hedenstierna, Jacob Widaeus, Emelie Arvidsson, Berit Hammas, Lena Grillner, et al. (+3)
36 [GO] 2023―Sep―13 Is molnupiravir a wise investment? Reassessing COVID-19 treatment strategies Chia Siang Kow, Dinesh Sangarran Ramachandram, Syed Shahzad Hasan
37 [GO] 2023―Aug―24 Impact of the COVID-19 pandemic on community antibiotic consumption in the EU/European Economic Area: a changepoint analysis Helene Vermeulen, Niel Hens, Lucy Catteau, Boudewijn Catry, Samuel Coenen
38 [GO] 2023―Aug―07 Effect of dapagliflozin on COVID-19 infection and risk of hospitalization Angel Salgado-Barreira, Jose Seijas-Amigo, Moises Rodriguez-Mañero, María Piñeiro-Lamas, Sonia Eiras, Alberto Cordero, et al. (+2)
39 [GO] 2023―Jul―12 Molnupiravir for the treatment of non-severe COVID-19: a systematic review and meta-analysis of 14 randomized trials with 34 570 patients Mingyao Sun, Honghao Lai, Jiajie Huang, Jianing Liu, Ying Li, Jinhui Tian, et al. (+4)
40 [GO] 2023―May―30 High-titer convalescent plasma plus nirmatrelvir/ritonavir treatment for non-resolving COVID-19 in six immunocompromised patients Sammy Huygens, Arvind Gharbharan, Yasmina Serroukh, Britt Snoek, Bas Franken, Bas B Oude Munnink, et al. (+4)
41 [GO] 2023―May―25 Triple antiviral treatment for COVID-19 in an immunocompromised patient Chiara Dentone, Malgorzata Mikulska, Chiara Sepulcri, Elisa Balletto, Vanessa De Pace, Sabrina Beltramini, Matteo Bassetti
42 [GO] 2023―May―25 Non-randomized evaluation of hospitalization after a prescription for nirmatrelvir/ritonavir versus molnupiravir in high-risk COVID-19 outpatients Kelsie Cowman, Alexander Miller, Yi Guo, Mei H Chang, Terrence McSweeney, Hongkai Bao, et al. (+11)
43 [GO] 2023―May―12 Efficacy and safety of molnupiravir for the treatment of SARS-CoV-2 infection: a systematic review and meta-analysis Jakob J Malin, Stephanie Weibel, Henning Gruell, Nina Kreuzberger, Miriam Stegemann, Nicole Skoetz
44 [GO] 2023―Apr―22 Real-life experience with remdesivir for treatment of COVID-19 among older adults: a multicentre retrospective study Ili Margalit, Giusy Tiseo, Marco Ripa, Vanni Borghi, Hefziba Green, Virginie Prendki, et al. (+9)
45 [GO] 2023―Apr―13 Current outcomes of SARS-CoV-2 Omicron variant infection in high-risk haematological patients treated early with antivirals Tommaso-Francesco Aiello, Pedro Puerta-Alcalde, Mariana Chumbita, Carlos Lopera, Patricia Monzó, Albert Cortes, et al. (+11)
46 [GO] 2023―Apr―11 Correction: The use of prophylactic nebulized liposomal amphotericin B to reduce the risk of CAPA in mechanically ventilated COVID-19 patients on ICU in a large UK tertiary teaching hospital trust
47 [GO] 2023―Mar―28 Point prevalence audit surveys of respiratory tract infection consultations and antibiotic prescribing in primary care before and during the COVID-19 pandemic in Ireland M Shah, A Fleming, T M Barbosa, A W van der Velden, S Parveen, A Vellinga
48 [GO] 2023―Mar―07 The use of prophylactic nebulized liposomal amphotericin B to reduce the risk of CAPA in mechanically ventilated COVID-19 patients on ICU in a large UK tertiary teaching hospital trust Anna Wild, Vicki Fleming, Lauren Rose, Amelia Joseph
49 [GO] 2023―Mar―04 Early initiation of three-drug combinations for the treatment of carbapenem-resistant A. baumannii among COVID-19 patients Emily L Heil, Kimberly C Claeys, Ellen G Kline, Tara M Rogers, Kevin M Squires, Alina Iovleva, et al. (+5)
50 [GO] 2023―Mar―01 Comment on ‘The dangers of non-randomized, observational studies. Experience from the COVID-19 epidemic’. Aspirin therapy in COVID-19: too soon to dismiss its benefits? Chia Siang Kow, Dinesh Sangarran Ramachandram, Syed Shahzad Hasan
51 [GO] 2023―Feb―15 A carbapenem-focused antimicrobial stewardship programme implemented during the COVID-19 pandemic in a setting of high endemicity for multidrug-resistant Gram-negative bacteria Nikolaos Spernovasilis, Evangelos I Kritsotakis, Anna Mathioudaki, Alexandra Vouidaski, Christos Spanias, Maria Petrodaskalaki, et al. (+3)
52 [GO] 2023―Feb―10 Efficacy comparison of 3CL protease inhibitors ensitrelvir and nirmatrelvir against SARS-CoV-2 in vitro and in vivo Takayuki Kuroda, Haruaki Nobori, Keita Fukao, Kaoru Baba, Kazumi Matsumoto, Shinpei Yoshida, et al. (+13)
53 [GO] 2023―Feb―06 Antimicrobial consumption and drug utilization patterns among COVID-19 and non-COVID-19 patients Bianca B P Antunes, Amanda A B Silva, Patricia H C Nunes, Ignacio Martin-Loeches, Pedro Kurtz, Silvio Hamacher, Fernando A Bozza
54 [GO] 2023―Jan―08 Evaluation of publication bias for 12 clinical trials of molnupiravir to treat SARS-CoV-2 infection in 13 694 patients with meta-analysis Jack M Lawrence, Manya Mirchandani, Andrew Hill
55 [GO] 2022―Dec―28 The dangers of non-randomized, observational studies: experience from the COVID-19 epidemic Andrew Hill, Manya Mirchandani
56 [GO] 2022―Dec―22 Successful use of nirmatrelvir/ritonavir in immunocompromised patients with persistent and/or relapsing COVID-19 Lucia Graziani, Leonardo Gori, Tommaso Manciulli, Gregorio Basile, Irene Campolmi, Beatrice Borchi, et al. (+12)
57 [GO] 2022―Oct―25 Outpatient purchasing patterns of hydroxychloroquine and ivermectin in the USA and Canada during the COVID-19 pandemic: an interrupted time series analysis from 2016 to 2021 Martin Ho, Mina Tadrous, Anita Iacono, Katie Suda, Tara Gomes
58 [GO] 2022―Sep―02 Impact of introducing procalcitonin testing on antibiotic usage in acute NHS hospitals during the first wave of COVID-19 in the UK: a controlled interrupted time series analysis of organization-level data-authors’ response Martin J Llewelyn, Robert M West, Enitan D Carrol, Philip Pallmann, Jonathan A T Sandoe
59 [GO] 2022―Aug―18 Global consumption of antimicrobials: impact of the WHO Global Action Plan on Antimicrobial Resistance and 2019 coronavirus pandemic (COVID-19)-authors’ response Tumader Khouja, Mina Tadrous, Katie J Suda
60 [GO] 2022―Aug―12 Randomized clinical trial of nitazoxanide or sofosbuvir/daclatasvir for the prevention of SARS-CoV-2 infection Simiso Sokhela, Bronwyn Bosch, Andrew Hill, Bryony Simmons, Joana Woods, Hilary Johnstone, et al. (+5)
61 [GO] 2022―Aug―01 Real-world effectiveness of early remdesivir and sotrovimab in the highest-risk COVID-19 outpatients during the Omicron surge Nicholas Piccicacco, Kristen Zeitler, Austin Ing, Jose Montero, Jonathan Faughn, Suzane Silbert, Kami Kim
62 [GO] 2022―Aug―01 Efficacy of ensitrelvir against SARS-CoV-2 in a delayed-treatment mouse model Haruaki Nobori, Keita Fukao, Takayuki Kuroda, Naomi Anan, Ryoichi Tashima, Masaaki Nakashima, et al. (+9)
63 [GO] 2022―Jul―25 Targeted SARS-CoV-2 treatment is associated with decreased mortality in immunocompromised patients with COVID-19 Emmanuel Lafont, Hélène Pere, David Lebeaux, Geoffrey Cheminet, Eric Thervet, Romain Guillemain, Adrien Flahault
64 [GO] 2022―Jul―23 Impact of the COVID-19 pandemic on hospital antimicrobial consumption in Croatia Vera Vlahović-Palčevski, Igor Rubinić, Marina Payerl Pal
65 [GO] 2022―Jul―18 Interpatient variability in the pharmacokinetics of remdesivir and its main metabolite GS-441524 in treated COVID-19 subjects Massimo Tempestilli, Tommaso Ascoli Bartoli, Domenico Benvenuto, Giulia Valeria Stazi, Luisa Marchioni, Emanuele Nicastri, Chiara Agrati
66 [GO] 2022―Jun―09 Impact of tenofovir on SARS-CoV-2 infection and severe outcomes among people living with HIV: a propensity score-matched study Daniel K. Nomah, Juliana Reyes-Urueña, Yesika Díaz, Sergio Moreno, Jordi Aceiton, Andreu Bruguera, et al. (+96)
67 [GO] 2022―Jun―07 Comment on: Impact of introducing procalcitonin testing on antibiotic usage in acute NHS hospitals during the first wave of COVID-19 in the UK: a controlled interrupted time series analysis of organization-level data Mei-Chin Su, James Yeongjun Park, Wan-Ting Hsu, Chung-Yen Huang, Chia-Chun Hsu, Chia-Hung Yo, Chien-Chang Lee
68 [GO] 2022―May―31 Comment on: Global consumption of antimicrobials: impact of the WHO Global Action Plan on Antimicrobial Resistance and 2019 coronavirus pandemic (COVID-19) Giorgia Sulis, Madhukar Pai, Sumanth Gandra
69 [GO] 2022―Apr―02 Correction to: Drug interactions: a review of the unseen danger of experimental COVID-19 therapies
70 [GO] 2021―Mar―11 Erratum to: Sofosbuvir/daclatasvir regimens for the treatment of COVID-19: an individual patient data meta-analysis Bryony Simmons, Hannah Wentzel, Sara Mobarak, Gholamali Eslami, Anahita Sadeghi, Ali Ali Asgari, et al. (+4)
71 [GO] 2020―Nov―19 Hydroxychloroquine pre-exposure prophylaxis for COVID-19 in healthcare workers Boris Revollo, Cristian Tebe, Judith Peñafiel, Ignacio Blanco, Nuria Perez-Alvarez, Ruth Lopez, et al. (+10)
72 [GO] 2020―May―18 COVID-19 and the potential long-term impact on antimicrobial resistance Timothy M Rawson, Luke S P Moore, Enrique Castro-Sanchez, Esmita Charani, Frances Davies, Giovanni Satta, et al. (+2)
73 [GO] 2020―May―18 Lopinavir pharmacokinetics in COVID-19 patients Matthieu Gregoire, Paul Le Turnier, Benjamin J Gaborit, Gwenaelle Veyrac, Raphaël Lecomte, David Boutoille, et al. (+4)
74 [GO] 2020―Mar―06 COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression Dan Zhou, Sheng-Ming Dai, Qiang Tong
 [1] 

74 Results       Page 1


[de][en]

Last change 2025―Jul―29 14:55:09 UTC

© Daten-Quadrat 2022       Done in 0.004 sec